J
Judith Feinberg
Researcher at University of Cincinnati
Publications - 137
Citations - 10167
Judith Feinberg is an academic researcher from University of Cincinnati. The author has contributed to research in topics: Medicine & Ritonavir. The author has an hindex of 46, co-authored 118 publications receiving 9841 citations. Previous affiliations of Judith Feinberg include University of Cincinnati Academic Health Center & University of Utah.
Papers
More filters
Journal ArticleDOI
A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or Less
Scott M. Hammer,Kathleen Squires,Michael Hughes,Michael Hughes,Janet M. Grimes,Lisa M. Demeter,Judith S. Currier,Joseph J. Eron,Judith Feinberg,Henry H. Balfour,Lawrence Deyton,Chodakewitz Jeffrey A,Margaret A. Fischl,John P. Phair,William Spreen,Louise Pedneault,Bach-Yen Nguyen,Jon C. Cook +17 more
TL;DR: In this article, the efficacy and safety of adding a protease inhibitor to two nucleoside analogues to treat human immunodeficiency virus type 1 (HIV-1) infection are not clear.
Journal ArticleDOI
Guidelines for preventing opportunistic infections among HIV-infected persons - 2002
Henry Masur,Jonathan E. Kaplan,King K. Holmes,Beverly Alston,Miriam J. Alter,Neil M. Ampel,Jean Anderson,A. Cornelius Baker,David A Barr,John G. Bartlett,John E. Bennett,Constance A. Benson,William A. Bower,Samuel A. Bozzette,John T. Brooks,Victoria A. Cargill,Kenneth G. Castro,Richard E. Chaisson,David A. Cooper,Clyde S. Crumpacker,Judith S. Currier,Kevin M. DeCock,Lawrence Deyton,Scott F. Dowell,W. Lawrence Drew,William Duncan,Mark S. Dworkin,Clare A. Dykewicz,Robert W Eisinger,Tedd Ellerbrock,Wafaa El-Sadr,Judith Feinberg,Kenneth A. Freedberg,Keiji Fukuda,Hansjakob Furrer,Jose M. Gatell,John W. Gnann,Mark J. Goldberger,Sue Goldie,Eric P. Goosby,Fred M. Gordin,Peter A. Gross,Rana Hajjeh,Richard Hafner,Diane Havlir,S D Holmberg,David R. Holtgrave,Thomas M. Hooton,Douglas A. Jabs,Mark A. Jacobson,Harold Jaffe,Edward N. Janoff,Jeffrey M. Jones,Dennis D. Juranek,Mari M. Kitahata,Joseph A. Kovacs,Catherine Leport,Myron J. Levin,Juan C. Lopez,Jens D Lundgren,Michael Marco,Eric Mast,Douglas L. Mayers,Lynne M. Mofenson,Julio Montaner,Richard A. Moore,Thomas Navin,James D. Neaton,Charles Nelson,Joseph F. O'Neill,Joel Palefsky,Alice Pau,Phil Pellett,John P. Phair,Steve Piscitelli,Michael A. Polis,Thomas C. Quinn,William C. Reeves,Peter Reiss,David Rimland,Anne Schuchat,Cynthia L. Sears,Leonard B. Seeff,Kent A. Sepkowitz,Kenneth E. Sherman,Thomas G. Slama,Elaine M. Sloand,Stephen A. Spector,John A. Stewart,David L. Thomas,Timothy M. Uyeki,Russell Van Dyke,M. Elsa Villarino,Anna Wald,D. Heather Watts,L. Joseph Wheat,Paige L. Williams,Thomas C. Wright +97 more
TL;DR: This fourth edition of the guidelines for preventing opportunistic infections (OIs) among persons infected with human immunodeficiency virus (HIV) is intended for clinicians and other health-care providers who care for HIV-infected persons.
Journal ArticleDOI
Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
Bonaventura Clotet,Judith Feinberg,Jan van Lunzen,Marie Aude Khuong-Josses,Andrea Antinori,Irina Dumitru,Vadim Pokrovskiy,Jan Fehr,Roberto Ortiz,Michael S. Saag,Julia Harris,Clare Brennan,Tamio Fujiwara,Sherene Min +13 more
TL;DR: Once-daily dolutegravir in combination with fixed-dose NRTIs represents an effective new treatment option for HIV-1-infected, treatment-naive patients.
Journal Article
Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis
Richard A. Lewis,P. Clogston,Victor Fainstein,R. Gross,Tobias Samo,C. Tuttle,Douglas A. Jabs,Linda G. Apuzzo,John Bartlett,James P. Dunn,L. Eldred,Judith Feinberg,T. Flynn,R. King,B. Barron,D. Greenspan,C. LeCount,Gholam A. Peyman,Murk-Hein Heinemann +18 more
Journal ArticleDOI
A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021
W D Hardy,Judith Feinberg,Dianne M. Finkelstein,M E Power,Weili He,C Kaczka,Peter T. Frame,M Holmes,Hetty A. Waskin,Robert J. Fass +9 more
TL;DR: In patients with AIDS who are receiving zidovudine, trimethoprim-sulfamethoxazole is more effective than aerosolized pentamidine in conventional doses for the prevention of recurrent pneumocystis infection.